GlassScriptPhysician profile
Mahin Baha
NPI 1881042869
$3,818.57
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $534 · 2021: $1,331 · 2022: $655 · 2023: $612 · 2024: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,124.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $724.75 | 2019-2024 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $486.58 | 2020-2024 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $429.07 | 2021-2024 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $365.10 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $320.56 | 2020-2021 | |
| Glaxosmithkline, LLC. | $247.05 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $234.02 | 2019-2024 | Airsupra |
| Astellas Pharma US INC | $139.46 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $127.38 | 2020-2022 | |
| Abbott Laboratories | $99.42 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.96 | 2019-2021 | |
| Amgen INC. | $67.52 | 2020-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $51.79 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $49.24 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $47.09 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $44.97 | 2023 | Ztlido |
| Merck Sharp & Dohme LLC | $35.43 | 2021 | |
| Genentech USA, INC. | $34.51 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $30.37 | 2019-2021 | |
| Ibsa Pharma INC. | $28.23 | 2020 | |
| Endo Pharmaceuticals INC. | $21.47 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.78 | 2024 | Xifaxan |
| Dexcom, INC. | $20.33 | 2022 | |
| Nevro Corp. | $18.06 | 2023 | Senza |
| Dermira, INC. | $17.90 | 2020 | |
| Eisai INC. | $17.87 | 2020 | |
| Exact Sciences Corporation | $17.17 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $15.42 | 2020 | |
| Shire North American Group INC | $15.07 | 2019 | |
| Fidia Pharma USA INC. | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahin Baha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.